

RESEARCH

Open Access



Activating A1 adenosine receptor signaling boosts early pulmonary neutrophil recruitment in aged mice in response to *Streptococcus pneumoniae* infection

Shaunna R. Simmons¹, Sydney E. Herring¹, Essi Y.I. Tchalla¹, Alexandra P. Lenhard¹, Manmeet Bhalla¹ and Elsa N. Bou Ghanem^{1*}

Abstract

Background *Streptococcus pneumoniae* (pneumococcus) is a leading cause of pneumonia in older adults. Successful control of pneumococci requires robust pulmonary neutrophil influx early in infection. However, aging is associated with aberrant neutrophil recruitment and the mechanisms behind that are not understood. Here we explored how neutrophil recruitment following pneumococcal infection changes with age and the host pathways regulating this.

Results Following pneumococcal infection there was a significant delay in early neutrophil recruitment to the lungs of aged mice. Neutrophils from aged mice showed defects in trans-endothelial migration in vitro compared to young controls. To understand the pathways involved, we examined immune modulatory extracellular adenosine (EAD) signaling, that is activated upon cellular damage. Signaling through the lower affinity A2A and A2B adenosine receptors had no effect on neutrophil recruitment to infected lungs. In contrast, inhibition of the high affinity A1 receptor in young mice blunted neutrophil recruitment to the lungs following infection. A1 receptor inhibition decreased expression of CXCR2 on circulating neutrophils, which is required for trans-endothelial migration. Indeed, A1 receptor signaling on neutrophils was required for their ability to migrate across endothelial cells in response to infection. Aging was not associated with defects in EAD production or receptor expression on neutrophils. However, agonism of A1 receptor in aged mice rescued the early defect in neutrophil migration to the lungs and improved control of bacterial burden.

Conclusions This study suggests age-driven defects in EAD damage signaling can be targeted to rescue the delay in pulmonary neutrophil migration in response to bacterial pneumonia.

Keywords Extracellular adenosine, Pneumococcus, PMNs, A1R, Pneumonia, Migration, Inflammation, Immunosenescence, Lung

*Correspondence:

Elsa N. Bou Ghanem
Elsaboug@buffalo.edu

¹Department of Microbiology and Immunology, School of Medicine, University at Buffalo, Buffalo, NY, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Streptococcus pneumoniae (pneumococcus) are encapsulated, Gram positive bacteria that are responsible for an estimated 1.6 million deaths each year [1]. *S. pneumoniae* remain the leading cause of community acquired bacterial pneumonia in individuals over the age of 65 [2–4]. Disease and mortality caused by these bacteria persist despite available vaccines and antibiotics [3, 5, 6]. Older adults are at an increased risk of infection and serious disease from pneumococcal pneumonia due to progressive deleterious molecular, cellular and systemic changes termed the “Hallmarks of Aging” [7, 8], that can affect the ability of the host to mount an efficient and balanced immune response. These hallmarks include aberrant genetic changes, altered metabolic responses, cellular senescence, and chronic inflammation [7, 8]. Cellular senescence affects several cell types including immune cells, causing them to be less efficient at pathogen clearance [7, 8]. Cellular senescence is also associated with increased production of pro-inflammatory cytokines leading to an increase in basal inflammation known as inflammaging [7, 8]. Increased inflammation with age contributes to a reduction in the ability of immune cells to respond to acute stimuli, further dysregulating the immune response [7–9]. A better understanding of how immune cell responses change with host aging upon pneumococcal infection, and the signaling pathways that control these responses, is necessary to promote better protection against disease.

An important mediator of host protection following pneumococcal pneumonia is the polymorphonuclear leukocyte (PMNs) response. PMNs also known as neutrophils, are the first cell to be recruited to the lungs following pneumococcal infection [10, 11] and this response is necessary for host protection. Individuals with neutropenia are more susceptible to pneumonia and experimental depletion of PMNs early in infection result in reduced ability to control bacterial numbers and accelerated death in murine models of infection [12, 13]. Upon pulmonary infection, PMNs are recruited from the circulation into the lung tissue where they kill bacteria via several antimicrobial effector functions, such as release of preformed antimicrobial granules, reactive oxygen species, phagocytosis, and neutrophil extracellular traps [14]. However, an effective PMN response in the pulmonary environment must be balanced, where PMNs need to be recruited in quickly to clear bacteria and then resolve. An exacerbated PMN response without resolution is damaging to host tissue due to the antimicrobial products produced by PMNs, and without proper resolution PMNs contribute to lung damage which worsens disease outcomes [12, 15]. There is evidence that PMN influx to the lungs later in infection is dysregulated with age as biopsy samples from older adults show an increase in the percentage of

PMNs in the lungs compared to younger patients following pneumococcal pneumonia, and this can be recapitulated in mouse models [16, 17]. However, how neutrophil recruitment changes with age early in infection, when PMNs are beneficial to the host in clearing the pathogen, and the pathways controlling PMN influx remain unexplored.

We previously found that the production of extracellular adenosine (EAD) is crucial for regulating PMN influx to the lungs in young mice [10]. Adenosine accumulates in the extracellular space as a result of cellular damage. Upon tissue injury by a variety of insults, including infection, ATP released from cells is metabolized to EAD by the sequential action of the extracellular ectonucleotidases CD39 and CD73 [18]. At baseline, EAD levels are very low/ undetectable in extracellular spaces but can increase more than 10-fold upon infection [19]. EAD can signal via 4 G-protein coupled receptors, A1, A2A, A2B and A3 that respond to EAD in a dose-dependent manner [18, 20]. A1 is high affinity and is activated by lower levels of adenosine while A2A and A2B are lower affinity and require higher levels of adenosine to become activated [18]. The different adenosine receptors are also coupled to different G proteins that can inhibit (G_i) or stimulate (G_s) adenylyl cyclase or activate phospholipase C (G_q), and therefore can have opposite effects on downstream signaling and cell function. These receptors are ubiquitously expressed on many cell types including PMNs [21].

Changes in EAD production and signaling occur with aging [22–27]. Although the role of this pathway in immunosenescence remains largely unexplored, we previously found that aging is accompanied by changes in expression of EAD enzymes on murine PMNs at baseline and that EAD signaling controlled PMN antibacterial function [21, 28, 29]. However, how the levels of extracellular adenosine and the receptors signaled through change after pneumococcal infection and across host age, and their role in PMN migration, is unknown. In this study, we asked how early PMN recruitment changes with host aging and if the extracellular adenosine pathway regulates that during bacterial pneumonia. We tested the hypothesis that signaling through the high affinity A1 adenosine receptor would be important early in pneumococcal infection when adenosine levels are lower to help draw the PMNs to the lung, while signaling through the lower affinity receptors may be required late in infection to help resolve PMN influx and that these dynamics change during host aging.

Methods

Mice

Young (8–12 weeks) and old (18–22 months) C57BL/6 (B6) male mice were obtained from the National Institute

on Aging colony or from Jackson Laboratories (Bar Harbor, ME). A2BR^{-/-} mice on a B6 background (B6.129P2-Adora2btm1Till/J) and A2AR^{-/-} mice on a Balb/c background (C;129 S-Adora2atm1Jfc/J) were purchased from Jackson Laboratory and bred at our facility. Wild type C57BL/6J and Balb/cJ mice were used as controls. Since males are more susceptible to pneumococcal infection compared to females [30] and due to the limited availability of aged cohorts, experiments were performed in male mice. All mice were housed at the University at Buffalo in specific pathogen free housing for at least 2 weeks before use in experiments. All experiments were conducted in accordance with the Institutional Animal Care and Use Committee guidelines.

Bacteria

Streptococcus pneumoniae TIGR4 strain (serotype 4) was a kind gift from Andrew Camilli. Briefly, bacteria were grown to mid-exponential phase at 37°C at 5% CO₂ in Todd Hewitt broth supplemented with 0.5% yeast extract and oxyrase as previously described [20].

PMN isolation

Bone marrow cells were collected from the femurs and tibias of uninfected mice by flushing with RPMI supplemented with 10% FBS and 2mM EDTA. Red blood cells were then lysed, and remaining cells were washed, and resuspended in PBS. PMNs were separated via density centrifugation using histopaque 1119 (Sigma, Catalogue number 11,191) and 1077 (Sigma, 10,771) as previously described [20, 21, 31, 32]. PMNs were then resuspended at the desired concentration in Hank's Balanced Salt Solution/0.1% gelatin with no Ca²⁺ or Mg²⁺ and kept on ice until use. The purity of PMNs was confirmed using flow cytometry and 85–90% of enriched cells were positive for Ly6G and CD11b.

Mouse infections and treatments

Mice were infected intratracheally (i.t.) with 50ul of *S. pneumoniae* TIGR4 at the indicated concentrations. Mice were first anesthetized using isoflurane and the bacterial inoculum pipetted into the trachea with the tongue gently pulled out to ensure direct delivery into the lungs. Following infection, mice were euthanized at the indicated time points, blood was collected by portal vein snip to determine bacteremia. Mice were then perfused with PBS through the right ventricle and the lungs harvested. Following harvest, the lungs were minced into small pieces, mixed well and half of each lung sample was homogenized in sterile PBS to plate for CFU, and the remaining half was digested and used for flow cytometry analysis. Lung and blood samples were diluted in sterile PBS and plated on blood agar to enumerate CFU. For experiments where the effect of A1 receptor signaling

was measured, the A1 receptor inhibitor, 8-Cyclopentyl-1,3-dipropylxanthine (C101) (DPCPX) [28, 33, 34] or A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine (C7938) [35] were purchased from Sigma Aldrich, dissolved in DMSO and filter sterilized by passing through a 0.22 µm filter prior to use. Mice were given intraperitoneal (i.p.) injections of 1 mg/kg of the A1 inhibitor or 0.1 mg/kg of the A1 agonist or vehicle control at -1 and 0 (immediately before challenge) days relative to infection. For experiments where the effect of A2A receptor signaling was measured, the A2A receptor inhibitor, 3,7-Dimethyl-1-propargylxanthine (D134) [36], or A2A receptor agonist CGS21680 (C141) [37], were purchased from Sigma, dissolved in DMSO and filter sterilized by passing through a 0.22 µm filter prior to use. Mice were given i.p injections of 5 mg/kg of the A2A antagonist or 2 mg/kg of the A2A agonist or vehicle control at -18 and 0 h, immediately before challenge for pre-treated (designated as PRE) and 18 h post challenge for post-treated groups (designated as POST). Control animals were treated with vehicle control.

PMN depletion

Neutrophils were depleted by intraperitoneal administration of 50ug of anti Ly6G antibody (clone IA8) or isotype IgG control (BD Pharmingen) 24 h prior to and at the time of infection [32].

PMN adoptive transfer

PMNs were isolated from the bone marrow of young and old uninfected mice. 2.5×10⁶ PMNs (in PBS) were then injected intraperitoneally into old mice. This method allows delivery of PMNs into the circulation and homing into organs in response to infection as we previously described [20]. One hour following transfer, old mice were infected i.t *S. pneumoniae* TIGR4. Mice were then euthanized at 6 hours post infection and the lung and blood collected for bacterial enumeration by plating on blood agar.

Flow cytometry

The lungs were digested into a single cell suspension in RPMI 1640 containing 10% FBS, 2 mg/mL type 2 collagenase (Worthington, CLS2) and 50 U/mL DNase (Worthington, DPRF) at 37 °C/ 5% CO₂ as previously described [20]. Blood was collected by portal vein snips in EDTA as an anticoagulant. Red blood cells were removed with a hypotonic lysis buffer (Fisher, A1049201). Cells were resuspended in FACS buffer (HBSS/ 1% FBS), treated with Fc block (anti-mouse clone 2.4G2) and stained with the following antibodies purchased from BD Biosciences or Invitrogen: Anti-Ly6G (IA8), anti-CD11b (M1/70), Anti-CD45 (30-F11). For adenosine receptor staining, the BD Cytotfix/Cytoperm kit (BD, 554,714) was

used to permeabilize the cells and the cells stained with the following unconjugated rabbit anti-adenosine receptor antibodies from Abcam as previously described [21]: A2a (ab3461), A2b (ab222901), A3 (ab203298) and A1 (ab82477). Rabbit polyclonal IgG (ab37415) was used as an isotype control and secondary PE-conjugated anti-Rabbit IgG was used (12,473,981; Invitrogen). Fluorescent intensities were measured on a BD Fortessa and at least 20,000 events were analyzed using FloJo.

Trans endothelial migration assay

To determine trans-endothelial migration of PMNs in vitro, C57BL/6 murine primary lung endothelial cells were grown according to manufacturer's protocol (Cell Biologics C57-6011) and 5 μ m transwells (Corning) were seeded at 10^6 cells/transwell and grown for 2 days at 37 °C/ 5% CO₂ until confluent. The bottom of the transwell was infected with *S. pneumoniae* TIGR4 at an MOI of 40. PMNs were isolated from the bone marrow of indicated mouse strains and 5×10^5 PMNs placed in the top of the transwell and incubated at 37 °C at 5% CO₂ for 1.5 h. The number of PMNs that migrated through the endothelial layer into the bottom of the transwell was determined by collecting the cells from the bottom well and lysing them with 10% Triton X-100 to release MPO. MPO was measured in each well by using 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABST) in the presence of hydrogen peroxide [10] and serial dilutions of a known numbers of PMNs were used to establish a standard curve, which was then used to quantify the number of migrated neutrophils as previously described [10].

Measurement of adenosine

Mice were infected i.t with *S. pneumoniae* TIGR4. Following infection, mice were euthanized at indicated time points and blood was collected and placed into microtainer tubes (BD) and centrifuged at 9000 rpm to collect sera. Circulating levels of adenosine were measured using the Adenosine Assay Kit (Fluorometric) from BioVision (AB211094) per manufacturer's instructions. Results were read using a Biotek plate reader.

Measurement of CXCL1

Levels of CXCL1 in lung homogenates were measured using ELISA following manufacturer's instructions (BioLegend, LEGEND MAX™ Mouse CXCL1 ELISA Kit 447507).

Statistics

Statistics were analyzed using Prism 9 (GraphPad). Bar graph and scatter plot data are presented as Mean \pm SD, and line graph data are presented as Mean \pm SEM. All data were tested for normality using Shapiro-Wilk test

prior to statistical analysis. Significant difference between groups was determined by Student's t-test, Mann-Whitney, Kruskal Wallis or one-way ANOVA as indicated. Difference in survival was determined by the log-rank (Mantel-Cox) test. *p* values < 0.05 were considered significant. * indicates $p < 0.05$, ** indicates $p < 0.001$, *** indicates $p < 0.0001$.

Results

Rapid PMN influx to the lungs following *S. pneumoniae* infection is impaired with aging

To determine how PMN influx to the lungs changes with age throughout the course of pneumococcal infection, young and aged mice were infected i.t. with 5×10^4 colony forming units (CFU) of *S. pneumoniae* TIGR4 and PMN recruitment to the lungs was measured by flow cytometry over time following infection. Young mice had significant PMN influx to the lungs within 6 h of infection, and further increase in pulmonary PMN numbers by 18 and 48 h post infection (hpi) (Fig. 1A). With age there was a delay in PMN influx early in infection with no increase from baseline by 6 h, but a significant increase by 18 and 48 hpi (Fig. 1A). When compared to young controls, aged mice had approximately 4-fold lower PMNs in the lungs at 6 hpi (Fig. 1A). By 18 and 48 hpi, PMNs were present in the lungs of aged mice at similar levels to young mice. To test if the decrease in PMN numbers in the lungs were due to lower numbers in the blood, we measured the number of circulating PMNs and found no difference at 6 and 18 hpi between young and old mice (Fig. 1B). The early delay in pulmonary presence was specific to PMNs as the numbers of alveolar macrophages, dendritic cells and recruited monocytes did not significantly differ, or were higher in old mice compared to young controls at 6 hpi (Fig S1A-D). As alveolar macrophage responses to pneumococci are known to decline with age and result in lower levels of chemokines/cytokines [9], we also measured production of CXCL1 in the lungs, a chemokine required from PMN recruitment to the lungs [38]. CXCL1 levels were slightly but not significantly higher in old mice compared to young controls (Fig S1C), suggesting that the defect in PMN pulmonary influx in old mice was not due to lower levels of CXCL1.

The delay in PMN influx to the lungs with age was associated with higher pneumococcal CFU in the lungs throughout the course of infection (Fig. 1C) and significantly higher bacteremia at 18 hpi (Fig. 1D). When normalized to bacterial burden, aged mice displayed significantly reduced PMN numbers in the lungs compared to young controls at 6 hours and significantly higher numbers of PMNs at 48 hpi (Fig S2A). To test if PMNs are required for early control of bacterial numbers, young mice were depleted of PMNs prior to i.t. infection with *S. pneumoniae* TIGR4. PMN depletion resulted in




Fig. 1 Old mice have delayed early pulmonary PMN influx. Young and old male C57BL/6 mice were infected i.t. with 5×10^4 CFU *S. pneumoniae* TIGR4. (A) Lungs and (B) blood were harvested and stained for PMNs and analyzed by flow cytometry at the indicated timepoints following infection. (C) Lung and blood (D) were collected, and samples plated on blood agar and CFU was enumerated at the indicated timepoint post infection. (E–F) Young male C57BL/6 mice were treated i.p. with PMN depleting anti-Ly6G antibodies or isotype control prior to infection with 5×10^4 CFU *S. pneumoniae* TIGR4 i.t. At 6 hpi lungs and blood were harvested and samples were plated on blood agar for enumeration of CFU. Pooled data are shown from two separate experiments with $n = 7$ mice per group. (F) Old male C57BL/6 mice were injected i.p. with 5×10^5 PMNs isolated from young and old mice. One hour post transfer, mice were infected with *S. pneumoniae* TIGR4 at 5×10^4 CFU and 6 hpi lungs were harvested and CFU was enumerated by plating on blood agar. Data are pooled from $n = 4$ mice per group. Asterisk indicates significant difference between indicated groups and as calculated by (A) Kruskal Wallis followed by Dunn’s multiple comparison test, (C and D) one-way ANOVA followed by Sidak’s multiple comparison test, and (E and F) unpaired Student’s t-test (lung) or Mann-Whitney test (blood). ns indicates non-significant

significant increase in bacterial numbers in the lung and in early systemic bacterial spread to the blood in half of depleted young mice (Fig. 1E). These findings show that early PMN presence is required for control of bacterial numbers. To test if PMNs from young hosts can rescue the early defect in control of pulmonary infection in old mice, aged hosts were adoptively transferred equal numbers (2.5×10^6 cells) of bone-marrow derived PMNs from uninfected young or old donors. The recipients were then infected with *S. pneumoniae* TIGR4 i.t. one hour post transfer and bacterial numbers in the lungs and blood were determined at 6 hpi. Old mice that received PMNs from young mice displayed a significant 10-fold decrease in bacterial numbers in the lungs compared to those that received PMNs from old donors (Fig. 1F). Similar to mice that did not receive any PMNs (Fig. 1D), no bacterial dissemination was detected at this early timepoint in any of the recipients. These findings indicate that with age there is an initial delay in neutrophil influx to the lungs

following pneumococcal infection that is associated with impaired bacterial control.

PMN trans-endothelial migration in response to *S. pneumoniae* is impaired with aging

For PMNs to enter the lungs to control pneumococcal infection, these cells must be recruited from the circulation and migrate through the endothelium to the infected pulmonary tissue. To better understand the age-related impairment in PMN influx, we measured neutrophil trans-endothelial migration. Using an in vitro transwell model, we measured neutrophil migration across primary mouse lung endothelial cells (isolated from young mice) in response to *S. pneumoniae* as a stimulus. At baseline there was no difference in neutrophil migration, however upon infection, there was a significant decline in the number of PMNs that migrated through the endothelial cell layer when PMNs were isolated from aged mice compared to young controls (Fig. 2). These data suggest that




Fig. 2 PMNs from old mice have a defect in trans-endothelial migration. PMNs were isolated from the bone marrow of young and old male C57BL/6 mice. Transwells were seeded with murine primary lung endothelial cells and the bottom of the transwell infected with *S. pneumoniae* TIGR4 at an MOI of 40. PMNs were placed in the top of the transwell and incubated at 37 °C at 5% CO₂ for 1.5 h. PMNs migrated to the bottom of each transwell were enumerated. Technical replicates are pooled from 4 separate experiments. Asterisk indicates significance as determined by unpaired Student's t-test




Fig. 3 Adenosine levels in circulation change with age over time Young and old male C57BL/6 mice were infected i.t. with 5×10^4 CFU *S. pneumoniae* TIGR4 and sera was collected at 6, 18, and 48 hpi. Adenosine levels in the circulation were measured from two separate experiments with $n=3$ mice at each individual time point. Asterisk indicates significantly different from young at the indicated timepoint as calculated by Kruskal Wallis followed by Dunn's multiple comparison test

there is an intrinsic defect in trans-endothelial migration by PMNs from aged mice.

***S. pneumoniae* infection alters expression of extracellular adenosine pathway components on PMNs**

To test if the extracellular adenosine (EAD) pathway regulates the age-driven changes in PMN pulmonary influx

following *S. pneumoniae* infection, we first needed to understand its role in young hosts. To do so, we tracked the expression of the different pathway components over time following infection (gating strategy Fig S3). As this is a pulmonary infection and the damage response is initiated in the lungs, we first tracked expression of the EAD producing and degrading enzymes in the lungs of young mice. We measured geometric mean florescence intensity (MFI) on total lung cells as an indicator of expression levels and found that the EAD producing enzymes CD39 and CD73 as well the EAD degrading enzyme ADA were expressed in the lung tissues and that their levels were maintained constant over 18 h of infection (Fig S4). We had challenges measuring EAD levels in the bronchioalveolar lavage fluid (not shown), so instead we assessed circulating levels and found overall levels of adenosine in the circulation did not significantly change over the course of infection in young mice (Fig. 3). We then tracked the expression of the four adenosine receptors on the surface of PMNs in the lungs using flow cytometry. We found that at baseline, the majority of PMNs in the lungs of young mice express A1, A2A, and A2B while only about half of PMNs express A3 on the cell surface (Fig. 4A). To determine if the level of receptor expression on PMNs changes over time, we stained for adenosine receptor expression following infection. We found that all four adenosine receptors showed a significant decrease in expression within the first 18 h of infection, followed by a recovery of levels comparable to baseline by 48 hpi in young mice (Fig. 4B). When we measured fold change from baseline, we observed around 2-fold decrease by 6 h for A2A and A2B and by 18 h for A1 and A3 followed by recovery for all four receptors by 48 hpi in young mice (Fig. 4C).

As PMNs are recruited from the blood, we also measured receptor expression in the circulation. In circulating PMNs of uninfected young mice, A1, A2A, and A2B receptors were highly expressed, however, very few PMNs expressed A3 (Fig. 5A). When we measured how receptor expression changes over time in circulating PMNs, we found that overall receptor expression remains constant in young mice (Fig. 5B). Unlike in the lungs, circulating PMNs in young mice expressed A2A, A2B, and A3 at similar level over the course of infection (Fig. 5C). The expression of A1 in the circulation showed a slight, but significant 1.5-fold decrease at 6 hpi but returned to baseline levels by 18 hpi (Fig. 5C). These data show that PMNs in the lungs and circulation of young mice express adenosine receptors on their surface, and that there are dynamic changes in adenosine receptor expression on circulating and pulmonary PMNs in response to pneumococcal infection.




Fig. 4 EAD pathway expression on pulmonary PMNs. Young and old male C57BL/6 mice were infected i.t. with 5×10^4 CFU *S. pneumoniae* TIGR4. The lungs were harvested, and lung digests were stained for PMNs and each adenosine receptor. Percent expression at baseline (**A**) and MFI over time (**B**) of the indicated adenosine receptor on PMNs was determined. Replicates are pooled from 6 separate experiments with $n=6-12$ mice per group. (**B**) # indicate significance from uninfected baseline as determined by Kruskal Wallis followed by Dunn's Multiple comparison test. (**C**) Asterix indicate significant difference from one as determined by a 1-sample t-test

Age-driven changes in EAD-pathway components following *S. pneumoniae* infection

We next wanted to understand how the adenosine pathway components change with host aging. We measured adenosine levels in the circulation of aged mice to see if the dysregulation in PMN influx was due to a lack of extracellular adenosine production. We found that early in infection, there was no significant difference in the amount of adenosine in the circulation when compared to young mice (Fig. 3). By 48 hpi, aged mice had significantly higher levels of adenosine (Fig. 3), suggesting exacerbated damage as the infection progressed in aged hosts, which fits with the higher bacterial loads observed in aged hosts (Fig. 1). When we measured adenosine pathway enzymes in the lungs, we found that at baseline, the lungs of aged mice express significantly higher amounts of the EAD producing enzymes CD73 and CD39, while the levels of the EAD degrading enzyme ADA were higher but did not reach statistical significance (Fig S4). When we tracked enzyme expression through the course of infection, we found that unlike young controls, the expression of all three enzymes had significantly decreased by 18 hpi in lungs of aged mice (Fig S4).

Next, we analyzed receptor expression on PMNs in the lungs and circulation. We found that in the lungs and

blood at baseline there was no change in the percentage of PMNs expressing A1, A2A, A2B, or A3 when compared to young mice with the majority of cells expressing A1, A2A, and A2B (Fig. 4A and Fig. 5A). To look at receptor expression changes overtime, we measured MFI and calculated fold change from baseline. In both lung (Fig. 4B) and blood (Fig. 5B) there was no significant difference in receptor expression between young and aged mice within the first 18 hpi. The expression of A1 receptor trended to be higher on circulating PMNs at 6 hpi in aged mice compared to young controls ($p=0.087$) (Fig. 5B). We did find that PMNs in the lungs of aged mice decreased levels of adenosine receptors early in infection respective to their own baseline (significance from own baseline indicated by #), however, unlike in young mice where receptor expression returned to baseline levels by 48 h, with age there was no rebound of adenosine receptor expression at this later time point (Fig. 4C). A similar pattern of decreased receptor expression over time in aged mice on circulating PMNs was also seen, where circulating PMNs maintained a significant 2-fold reduction (significance in fold-change from own baseline indicated by *) in expression of A1, A2A and A2B following infection (Fig. 5C). These data show that there is no defect with age in production of extracellular adenosine and




Fig. 5 EAD pathway expression on circulating PMNs. Young and old male C57BL/6 mice were infected i.t. with 5×10^4 CFU *S. pneumoniae* TIGR4. Blood was collected and stained for PMNs and adenosine receptors. Percent expression at baseline (A) and MFI over time (B) was determined using flow cytometry. Replicates are pooled from 4 separate experiments with $n=6-9$ mice per group. Asterisk indicate significant difference as determined by unpaired students t-test (A) and significantly different from one as determined by 1-sample t-test (C). (B) # indicate significance from uninfected baseline as determined by Kruskal Wallis followed by Dunn's Multiple comparison test

or adenosine receptor expression on PMNs. Rather, the decrease in adenosine receptor expression on PMNs during the course of infection is more pronounced and may result in decrease responsiveness to adenosine signaling in the aged hosts.

A2B adenosine receptor plays no role in PMN pulmonary influx following *S. pneumoniae* infection


To determine if the individual adenosine receptors played a role in PMN pulmonary migration, we focused on the receptors highly expressed on PMNs (A1, A2A and A2B). We first examined the A2B receptor. To examine the role of this receptor in PMN influx to the lungs in vivo, WT C57BL/6 and A2BR^{-/-} mice were infected intratracheally with 5×10^4 CFU *S. pneumoniae* and the total number of PMNs in the lungs was determined by flow cytometry at 6, 18, and 48 hpi. We found that there was no difference in the total amount of PMNs in the lungs at any of the time points tested between the mouse strains (Fig. 6A). Bacterial burden in the lungs also did not differ (Fig. 6B), supporting what was previously published [39] and even when normalized for bacterial numbers, PMN influx into the lungs in response to *S. pneumoniae* infection was comparable between WT and A2BR^{-/-} mice (Fig S2B). These data suggest that A2B receptor signaling does

not regulate PMN influx to the lung of *S. pneumoniae* infected mice.

A2A adenosine receptor plays no role in PMN pulmonary influx following *S. pneumoniae* infection

Next, we examined the role of A2A receptor signaling in PMN influx to the lungs following infection. To examine the role of this receptor in vivo, A2AR^{-/-} and WT BALB/c controls were infected intratracheally with 5×10^4 CFU *S. pneumoniae* TIGR4 and total number of PMNs in the lungs was determined at 6 and 48 hpi by flow cytometry. There was no difference in the number of PMNs in the lungs of A2AR^{-/-} or WT mice at either time point (Fig. 7A). To confirm that this result was not due to differences in bacterial burden, we analyzed *S. pneumoniae* CFU in both the lung (Fig. 7B) and blood (Fig. 7C) and found no difference in bacterial burden across mouse strains. Additionally, there was no difference in survival following infection between A2AR^{-/-} and WT mice (Fig. 7D). Since these experiments were done using mice on a Balb/c background, we also analyzed the role of A2A in C57BL/6 mice using a specific pharmacological A2A receptor inhibitor, 3,7-Dimethyl-1-propargylxanthine. We first tested the role of A2A early in infection by treating mice with the A2A receptor antagonist or vehicle control 18 h prior to bacterial

A.



B.




Fig. 6 A2B receptor does not affect PMN pulmonary numbers in vivo WT and A2BR^{-/-} mice were infected i.t with 5×10^4 CFU *S. pneumoniae* TIGR4. At the indicated timepoints following bacterial challenge, lungs were harvested and (A) stained for PMNs and analyzed by flow cytometry or (B) plated on blood agar plates for CFU enumeration. Data are pooled from 4 separate experiments with $n=6-8$ mice per group

challenge (PRE). We found no difference in total number of PMNs in the lungs (Fig S5A), total bacterial burden in the lung (Fig S5B) or bacteremia (Fig S5C) by 48 hpi. Similarly, inhibition of A2A prior to infection had no effect on mouse survival (Fig S5D). As A2A is a lower affinity receptor that may play a role later in infection as damage and EAD levels build up, we also tested its role later in infection, by timed inhibition 18 h post (POST) bacterial challenge. Again, we found no difference in total bacterial burden in the lung (Fig S5B) or bacteremia (Fig S5C) by 48 hpi in POST treated mice. However, there was a decrease in survival in the mice treated with A2A receptor inhibitor post infection (Fig S5D) suggesting that A2A receptor may play a protective role later in infection. Overall, these data suggest that A2A receptor signaling does not regulate PMN influx to the lungs of young mice following *S. pneumoniae* challenge.

A1 receptor signaling is required for PMN pulmonary influx in response to *S. pneumoniae* infection

To determine the role of A1 receptor signaling in PMN migration, young mice were treated i.p. with a specific A1 receptor inhibitor (whose specificity we confirmed in prior publications [28, 33] or vehicle control. Mice were then infected intratracheally with 5×10^4 CFU *S. pneumoniae* TIGR4 one day post drug treatment. Total PMN influx to the lungs of infected mice was measured by flow cytometry at 6, 18, and 48 h. We found that inhibition of A1 resulted in a significant delay in PMN influx to the lungs at 6 hpi (Fig. 8A-B). At 6 hpi, there was a significant decrease in total PMN numbers in the lungs (Fig. 8A)

and the amount of MPO (a marker of PMNs) in lung homogenates (Fig. 8B) of A1 inhibited mice. To understand the mechanism of the decline in PMN recruitment, we examined the expression of CD18 and CXCR2 on the surface of PMNs in the circulation. We found no difference in the numbers of circulating PMNs in A1 receptor inhibited versus vehicle treated mice (Fig S6). We further found that while A1 receptor inhibition had no effect of CD18 expression (Fig. 8C), it significantly reduced CXCR2 expression at 6 hpi (Fig. 8D), the time point at which PMN number in the lungs is lower (Fig. 8A). As CXCR2 was reported to be required for trans-endothelial migration in response to pneumococcal infection [11, 14, 38, 40, 41], we directly assessed the role of A1 on PMN trans-endothelial migration. Young mice were treated i.p. with an A1 receptor inhibitor, and PMNs were then isolated, and trans-endothelial migration was measured using the same in vitro transwell assay described above. A1 receptor inhibited PMNs displayed a significant decrease in their ability to migrate trans-endothelially compared to VC treated PMNs, indicating that A1 signaling on PMNs is required for efficient trans-endothelial migration (Fig. 8E). These data suggest that A1 adenosine receptor signaling is required for recruitment of PMNs to the lungs in response to *S. pneumoniae* infection.

Activation of A1 receptor signaling rescues the ability of PMNs from old mice to be recruited to the lungs following *S. pneumoniae* infection

To better understand if adenosine receptor signaling can be targeted to reverse the age associated dysregulation in




Fig. 7 A2A receptor does not affect PMN pulmonary numbers or host resistance to infection. **(A)** WT and A2AR^{-/-} mice were infected i.t. with 5×10^4 CFU *S. pneumoniae* TIGR4. At the indicated timepoints following bacterial challenge, lungs were harvested, digested, and stained for PMNs and analyzed by flow cytometry. Data are pooled from 3 separate experiments with $n=4-6$ mice per group. Lungs **(B)** and Blood **(C)** were harvested at indicated timepoints and plated on blood agar plates and CFU was enumerated. Data were pooled from 2 separate experiments with **(C)** $n=11-12$ mice per group and **(B)** $n=6$ mice per group. **(D)** WT and A2AR^{-/-} mice were infected as in **(A)** and monitored for survival. Data are pooled from 2 experiments with $n=11-12$ mice per group. No significant differences were found in survival as measured by Log-Rank (Mantle Cox) test

PMN pulmonary influx following pneumococcal infection, aged mice were treated with specific adenosine receptor agonists to stimulate receptor signaling and then infected intratracheally with *S. pneumoniae* TIGR4. We first tested A2A receptor as it had a role in controlling survival of young hosts later in infection. We found that activating A2A in aged mice at 18 hpi had no effect on the total number of PMNs in the lungs (Sup. Figure 7 A), or the number of bacteria in the lungs (Sup. Figure 7B), or blood (Sup. Figure 7 C) by 48 h post challenge.

We then focused on the role of A1 as it was required for early recruitment of PMNs in young hosts. We tested the effect of A1 agonism in aged mice and determined the total number of PMNs in the lungs at 6 hpi by flow cytometry. We found that agonism of the A1 receptor significantly increased the total number of PMNs in the lungs of aged mice 6 hpi when compared to uninfected mice (Fig. 9A). Additionally, at 6 hpi, a separate

set of A1 agonist treated mice had significantly higher levels of MPO in the lungs compared to vehicle control treated mice (Fig. 9B). In examining mechanisms, at 6 hpi, CXCR2 expression on circulating PMNs from old mice did not differ from young controls and A1 agonism did not significantly alter CXCR2 expression on PMNs in the blood of old mice (Fig. 9C). Importantly, A1 receptor agonism decreases bacterial burden in the lungs of aged mice compared to untreated controls (Fig. 9D). Taken together, these data demonstrate that A1 adenosine receptor signaling can be targeted to reverse the age-related decrease in PMN pulmonary influx and reduce bacterial burden in the lungs of infected aged mice.

Discussion

Cellular damage resulting from infection is proposed to shape the outcome of host-pathogen interactions [42–44] and damage-associated molecular patterns (DAMPs) can




Fig. 8 A1 receptor signaling is required for PMN pulmonary influx. **(A)** Young, male mice were treated i.p. with A1 inhibitor DPCPX and infected i.t. with 5×10^4 CFU *S. pneumoniae* TIGR4. At the indicated time points, lungs were harvested, digested, and stained for PMNs (CD45+, Ly6G + CD11b+) **(A)** and analyzed by flow cytometry. **(B)** Lungs of a separate set of treated and infected mice were harvested 6 hpi, homogenized and MPO levels were determined by ELISA. **(C–D)** Blood was harvested from infected and A1 treated mice (same mice as **A**) at the indicated time points and stained for PMNs and CD18 **(C)** or CXCR2 **(D)**. **(A, C and D)** Data are pooled from 3 separate experiments with $n = 6–12$ mice per group. **(A and D)** Asterix indicate significance as determined by Kruskal Wallis followed by Dunn's multiple comparison test. **(B)** Asterix indicate significance as determined by unpaired students t-test. **(E)** Young, male C57/B6 mice were treated i.p. with A1 inhibitor DPCPX or vehicle control (VC) and PMNs were isolated from the bone marrow. PMN migration across primary endothelial cells in response to *S. pneumoniae* TIGR4 infection was measured. Technical replicates are pooled from 4 separate experiments. Asterix indicates significance as determined by Mann-Whitney test

act as signals that initiate the immune response [45]. One such molecule is extracellular adenosine (EAD). At baseline homeostatic levels, adenosine levels in extracellular microenvironments are very low, however, upon tissue damage resulting from insults such as infection, EAD levels can rise more than 10-fold [18]. We previously found that EAD production and signaling are crucial for host resistance against pneumococcal infection [10, 20, 21, 39, 46]. We show here that the high affinity extracellular adenosine A1 receptor is required for initiating the recruitment of PMNs into the lungs following bacterial challenge. This initiation of early PMN recruitment was defective in aged hosts but could be reversed by activation of A1 receptor signaling, suggesting that with age there are changes in extracellular adenosine signaling that impair the ability of PMNs to rapidly respond to pneumococcal infection. One of the hallmarks of aging is altered intercellular communication, including endocrine and neuronal signaling [7] and the findings here suggest that damage signaling is also altered with aging and contributes to the age-driven changes in immune response to infection.

PMNs have a dynamic role during pneumococcal pneumonia with their early presence in the lungs being protective vs. later persistence being detrimental [47]. In murine models of infection, PMN influx to the lungs within the first 12 hpi correlated with control of bacterial burden and as confirmed here, PMN depletion prior to infection resulted in increased bacterial burden in the lung and host lethality [48, 49]. In humans, patients with neutropenia are at an increased risk for pneumonia [13]. These findings indicate that early influx of PMNs to the lungs is required for host protection against pneumococcal pneumonia. In contrast, PMN persistence in the pulmonary environment promotes disease [10, 15, 17]. Depletion of PMNs 18 h after pneumococcal lung infection resulted in reduced bacterial numbers and reduced lethality [10]. These findings demonstrate that the ability of PMNs to kill pneumococci is altered during infection [10]. Here we found that with aging there is a delay in PMN influx early within the first 6 h of infection accompanied by persistent presence in higher levels later in infection compared to young mice infected with the same dose of *S. pneumoniae*. This delay left aged mice more




Fig. 9 A1 receptor signaling rescues defect in early PMN pulmonary influx in aged mice. **(A)** Old male mice were treated i.p. with A1 agonist 2-Chloro-N⁶-cyclopentyladenosine or Vehicle Control and infected i.t. with 5×10^4 CFU *S. pneumoniae* TIGR4 for 6 h. Lungs were harvested, digested, and stained for PMNs and analyzed by flow cytometry. Data are pooled from two separate experiments and with $n=3$ uninfected and $n=6$ infected mice per group. Asterisk indicates significance as determined by One-way ANOVA followed by Sidak's multiple comparison test. ns indicates non-significant. **(B)** Lungs of a separate set of treated and infected mice were harvested 6 hpi, homogenized and MPO levels were determined by ELISA. Data are pooled from $n=3$ mice. Asterisk indicates significance as determined by unpaired Student's t-test. **(C)** Blood was harvested from infected young VC and old VC, or old A1 agonist treated mice at 6 hpi and stained for CXCR2 expression on PMNs. Data are pooled from two separate experiments and with $n=6$ mice per group. **(D)** Lung homogenates from infected mice were plated on Blood agar and bacterial CFU was enumerated. Data are pooled from two separate experiments and with $n=6$ infected mice per group. Asterisk indicates significance as determined by unpaired Student's t-test

susceptible to disease as it was accompanied by increased early bacterial burden in the lungs compared to young mice, that could be rescued by adoptive transfer of PMNs from young but not old hosts. Therefore, with age there is a delay in the protective early PMN recruitment to the site of infection. The majority of studies examining PMN influx in response to infection in aged hosts have focused on later timepoints [9, 10, 17, 50, 51]. In humans, elderly pneumococcal pneumonia patients had higher percentages of neutrophils in terminal lung biopsies compared to younger patients [16] and in several animal models of bacterial and viral pneumonia, PMN numbers in the lungs of aged mice were higher than in young controls at later timepoints [9, 10, 17, 50, 51], similar to what we found here. The dynamics of earlier influx and how that is altered with aging have not been as thoroughly addressed in the literature and there are no data from human pneumococcal pneumonia patients. Our findings suggest that the kinetics of PMN influx to the lungs in response to pneumococcal pneumonia is altered with age.

Following lung challenge, *S. pneumoniae* localizes within the airways and binds to lung tissues as well [10, 17]. For PMNs to reach the site of infection in the lungs, they have to move from the circulation across the endothelium, enter the interstitial space, then migrate across the lung epithelium into the airways [11, 52]. We found here that PMN migration across pulmonary endothelial cells is impaired with aging. Prior work found that

PMNs from elderly human donors did not show defects in transepithelial migration in response to pneumococcal infection [53] but rather that chemotaxis (or directional movement) of PMNs is diminished with aging [51, 54–58]. PMNs isolated from both healthy controls and pneumonia patients above 60 years of age displayed diminished chemotaxis compared with younger individuals [54, 55] which was linked to over activation of phosphoinositide-3-kinase (PI3K) signaling [54]. PI3K is controlled downstream of GPCRs including adenosine receptors [54, 59]. Here we found that A1 receptor signaling on PMNs is required for their migration across pulmonary endothelial cells in response to infection and that activating A1 receptor reverses the defect in early PMN pulmonary influx observed in aged hosts. These findings are supported by prior work showing that A1 receptor signaling on PMNs is required for their adherence to the endothelium in response to N-Formylmethionyl-leucyl-phenylalanine (fMLP) or Phorbol 12-myristate 13-acetate (PMA) stimulation [60, 61]. In this study we found that A1 receptor signaling was needed for the ability of PMNs from young mice to upregulate the expression of the chemokine receptor CXCR2 early on in response to infection. During *S. pneumoniae* infection, CXCR2 is required for PMN influx to the lungs [38] and in aged mice, expression of CXCR2 on PMNs was reported to be lower than young hosts [56]. However, here we found no difference in expression of CXCR2 on circulating

PMNs from young and old mice at 6 hpi and A1 agonism of old mice did not significantly change CXCR2 expression on PMNs. This suggests that activating A1 receptor signaling in aged hosts boosts PMN migration by other mechanisms.

The role of A1 receptor signaling in PMN recruitment to the lungs seem to play opposing roles during pathogen driven vs. sterile injury. In LPS or ischemia reperfusion lung injury, A1 receptor signaling attenuated PMN trafficking to the lungs [62–65]. In contrast and similar to what we observed here, A1 receptor signaling was required for PMN pulmonary influx during infection with H1N1 influenza virus [66]. This highlights that pathogens can alter the dynamics of the immune response and that the role of the adenosine signaling may differ in sterile vs. infection driven injury.

Extracellular adenosine is known to regulate PMN function [18] and play an important role in host resistance against pulmonary infections [67]. Aging is associated with aberrant PMN responses and overall increased susceptibility to pulmonary infections [47]. However, surprisingly, the role of EAD in immunosenescence remains largely unexplored. In prior work we found that there are age driven changes in the expression of the enzymes that make and break EAD on PMNs and that EAD signaling on PMNs could be targeted to reverse the decline in their antibacterial activity [33]. In this study, to examine the role extracellular adenosine signaling in the age-related delay in PMN influx, we tracked how this pathway changes with host aging. We found that circulating levels of adenosine were no different in young and aged mice, in fact aged mice had significantly more adenosine in circulation at 48 hpi. While this increase in adenosine later in infection may reflect the increased damage that is occurring in these mice (due to higher bacterial burden), these data also indicate that it is not that adenosine is not being produced with age, but that EAD signaling in PMNs of aged mice may be dysregulated. This is in line with prior work showing that aging is associated with defects in overall GPCR signaling and that alterations in EAD receptor signaling contribute to the age-associated decline of brain and heart organ functions [23, 25, 68]. When looking at adenosine receptor expression on the surface of PMNs from aged mice following pneumococcal infection, there was a decrease in receptor expression from baseline in both young and aged mice. However, in PMNs isolated from young mice these receptor levels rebounded by 48hpi, while receptor expression on PMNs from aged mice did not recover. Following activation by an agonist, GPCR signaling is desensitized by internalization of the receptor into the cell, this is a result of interaction of the G protein with β -arrestins to stop signaling and additional scaffold proteins which guide trafficking the internalized GPCR [69–71]. The

decrease in adenosine receptor expression following pneumococcal infection may be due to this process of GPCR desensitization. Following desensitization, GPCRs may be degraded but may also recycle back to the cell membrane surface for resensitization, where the receptor can be activated again [70]. In PMNs isolated from aged mice adenosine receptor expression does not rebound following the initial drop post infection. This would indicate that EAD receptors are not being recycled back to the cell surface, and throughout infection, PMNs of aged mice may be less responsive to activation by adenosine. This could be in part driven by the consistently elevated levels of EAD later in infection observed in old but not young hosts. Additionally, the differences in receptor levels between young and aged mice later in infection could indicate that there are changes in GPCR desensitization and re-sensitization in PMNs with host age.

A balanced PMN response where PMNs are recruited to the lungs and resolve at the proper time is essential for effective clearance of pneumococcus and efficient host protection [12, 13, 15, 16]. In prior work, we found that in young mice, EAD production by CD73 was needed for regulation of PMN influx later on during infection, where by day 2 following pulmonary challenge, CD73^{-/-} mice had significantly more PMNs in the lungs compared to wildtype controls [10]. We hypothesized that extracellular adenosine signaling via the low affinity receptors A2A and A2B receptors regulate PMN resolution from the lungs later in infection when adenosine levels are higher due to increased inflammation and host damage. It has been shown previously that under hypoxia conditions adenosine produced by the endothelium reduced PMN accumulation by activating A2A and A2B receptors on the PMN surface [72]. Surprisingly, we found here that young mice lacking A2A or A2B receptors showed no changes in PMN presence in the lungs through the course of pneumococcal infection. As both A2A or A2B receptors are expressed on PMNs and are coupled to Gs [18], it is possible that they play a redundant role in PMN movement and that removal of both would be needed to observe a significant effect. An alternative explanation is that the levels of adenosine receptors do decline on PMNs through infection even in young hosts, suggesting that PMNs may become less responsive to adenosine signaling with time.

In summary, we have shown that A1 receptor signaling is required for early PMN influx to the lungs following pneumococcal infection. Importantly, activation of the A1 receptor using A1 receptor agonist, 2-Chloro-N6-cyclopentyladenosine increased PMN influx to the lung in aged mice, which resulted in lower bacterial burden in the lung early in infection. This early control of bacterial numbers is likely crucial for host defense as prior work found that A1 agonism throughout the first 7 days of

infection significantly increased survival of old mice following pulmonary challenge with *S. pneumoniae* [46]. The enhanced ability to control bacterial infection could be a combination of increase PMN influx as shown here and improved function as previously reported [33]. A1 receptor is also expressed on cell types other than PMNs, including pulmonary epithelial cells and was reported to reduce bacterial binding to the pulmonary epithelium [46]. Therefore, the effect of A1 agonism in controlling bacterial numbers in aged hosts could be due to a combination of factors. These findings suggest that extracellular adenosine signaling may be dysregulated with host aging and that pharmacologically targeting this pathway can enhance the immune response in aged mice leading to more effective clearance of pneumococcus. Identifying a potential target to enhance the immune response to pneumococcal pneumonia in aged hosts is important as this disease persists in older adults despite the availability of antibiotics and vaccines [3, 5, 6]. In addition to being a potential pharmacological target, the extracellular adenosine pathway is an important pathway to understand in the context of host-pathogen interaction as it could be a marker of host damage. This study adds dysregulation of the EAD pathway with age under the aging hallmark of altered intercellular signaling, which in turn controls immunosenescence.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12979-024-00442-3>.

Supplementary Material 1

Acknowledgements

We would like to thank Dr. Michael Battaglia for critical feedback on the manuscript.

Author contributions

SRS designed research, conducted research, analyzed data, and wrote paper. SES designed research, conducted research, and analyzed data. EYIT, APL and MB conducted research and analyzed data. ENBG designed research, wrote the paper, and had responsibility for final content. All authors read and approved the final manuscript.

Funding

This work was supported by National Institute of Health grants R00AG051784 and R01 AG068568-01A1 to ENBG and F31 AI169889-01A1 to SRS.

Data availability

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Declarations

Ethics approval and consent to participate

All animal experiments were conducted in accordance with the Institutional Animal Care and Use Committee guidelines under the approved protocol number MIC33018Y.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 10 April 2024 / Accepted: 29 May 2024

Published online: 05 June 2024

References

1. WHO. Pneumococcal disease. World Health Organization. 2014.
2. Grudzinska FS, Brodlić M, Scholefield BR, Jackson T, Scott A, Thickett DR, et al. Neutrophils in community-acquired pneumonia: parallels in dysfunction at the extremes of age. *Thorax*. 2020;75(2):164–71.
3. Simell B, Vuorela A, Ekstrom N, Palmu A, Reunanen A, Meri S, et al. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of *Streptococcus pneumoniae* by neutrophil phagocytosis. *Vaccine*. 2011;29(10):1929–34.
4. Gonçalves MT, Mitchell TJ, Lord JM. Immune ageing and susceptibility to *Streptococcus pneumoniae*. *Biogerontology*. 2016;17(3):449–65.
5. CDC. Pneumococcal Disease Global Pneumococcal Disease and Vaccine CDC. Centers for Disease Control and Prevention; 2018 [updated 2018, November 15]. <https://www.cdc.gov/pneumococcal/global.html>
6. Matanock ALG, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥ 65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep*. 2019;68:1069–1075. CDC; 2019.
7. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell*. 2013;153(6):1194–217.
8. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. *Cell*. 2023;186(2):243–78.
9. Boyd AR, Shivshankar P, Jiang S, Berton MT, Orihuela CJ. Age-related defects in TLR2 signaling diminish the cytokine response by alveolar macrophages during murine pneumococcal pneumonia. *Exp Gerontol*. 2012;47(7):507–18.
10. Bou Ghanem EN, Clark S, Roggensack SE, McIver SR, Alcaide P, Haydon PG, et al. Extracellular Adenosine protects against *Streptococcus pneumoniae* lung infection by regulating Pulmonary Neutrophil Recruitment. *PLoS Pathog*. 2015;11(8):e1005126.
11. Palmer CS, Kimmey JM. Neutrophil Recruitment in Pneumococcal Pneumonia. *Front Cell Infect Microbiol*. 2022;12.
12. Pechous RD. With friends like these: the Complex Role of neutrophils in the progression of severe pneumonia. *Front Cell Infect Microbiol*. 2017;7:160.
13. Rolston KV. The spectrum of pulmonary infections in cancer patients. *Curr Opin Oncol*. 2001;13(4):218–23.
14. Kolaczowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. *Nat Rev Immunol*. 2013;13(3):159–75.
15. Bhowmick R, Tin Maung NH, Hurley BP, Ghanem EB, Gronert K, McCormick BA, et al. Systemic disease during *Streptococcus pneumoniae* acute lung infection requires 12-lipoxygenase-dependent inflammation. *J Immunol*. 2013;191(10):5115–23.
16. Menter T, Giefing-Kroell C, Grubeck-Loebenstien B, Tzankov A. Characterization of the inflammatory infiltrate in *Streptococcus pneumoniae* pneumonia in young and elderly patients. *Pathobiol J Immunopathol Mol Cell Biol*. 2014;81(3):160–7.
17. Bou Ghanem EN, Clark S, Du X, Wu D, Camilli A, Leong JM, et al. The alpha-tocopherol form of vitamin E reverses age-associated susceptibility to streptococcus pneumoniae lung infection by modulating pulmonary neutrophil recruitment. *J Immunol*. 2015;194(3):1090–9.
18. Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine. *Arterioscler Thromb Vasc Biol*. 2012;32(4):856–64.
19. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat Rev Drug Discovery*. 2008;7(9):759–70.
20. Siwapornchai N, Lee JN, Tchalla EYI, Bhalla M, Yeoh JH, Roggensack SE et al. Extracellular adenosine enhances the ability of PMNs to kill *Streptococcus pneumoniae* by inhibiting IL-10 production. *J Leukoc Biol*. 2020.
21. Bhalla M, Simmons SR, Abamonte A, Herring SE, Roggensack SE, Bou Ghanem EN. Extracellular adenosine signaling reverses the age-driven decline

- in the ability of neutrophils to kill *Streptococcus pneumoniae*. *Aging Cell*. 2020;e13218.
22. Chen JF, Chern Y. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. *Handb Exp Pharmacol*. 2011;200:267–310.
 23. Willems L, Ashton KJ, Headrick JP. Adenosine-mediated cardioprotection in the aging myocardium. *Cardiovasc Res*. 2005;66(2):245–55.
 24. Headrick JP. Impact of aging on adenosine levels, A1/A2 responses, arrhythmogenesis, and energy metabolism in rat heart. *Am J Physiol*. 1996;270(3 Pt 2):H897–906.
 25. Mackiewicz M, Nikonova EV, Zimmermann JE, Romer MA, Cater J, Galante RJ, et al. Age-related changes in adenosine metabolic enzymes in sleep/wake regulatory areas of the brain. *Neurobiol Aging*. 2006;27(2):351–60.
 26. Crosti F, Ciboddo GF, Barbieri MC, Inversi F, Pavoni D, Quarenghi S, et al. Evidence for adenosine adenosine deaminase lymphocyte system impairment in ageing. *Bollettino dell'Istituto Sieroterapico Milanese*. 1987;66(4):282–8.
 27. Yeo EJ, Park SC. Age-dependent agonist-specific dysregulation of membrane-mediated signal transduction: emergence of the gate theory of aging. *Mech Ageing Dev*. 2002;123(12):1563–78.
 28. Bhalla M, Hui Yeoh J, Lamneck C, Herring SE, Tchalla EYI, Heinzinger LR et al. A1 adenosine receptor signaling reduces *Streptococcus pneumoniae* adherence to pulmonary epithelial cells by targeting expression of platelet-activating factor receptor. *Cell Microbiol*. 2019:e13141.
 29. Bhalla M, Heinzinger LR, Morenikeji OB, Marzullo B, Thomas BN, Bou Ghanem EN. Transcriptome profiling reveals CD73 and age-driven changes in neutrophil responses against Streptococcus pneumoniae. *bioRxiv*. 2021:2021.04.14.439887.
 30. Gutierrez F, Masia M, Mirete C, Soldan B, Rodriguez JC, Padilla S, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. *J Infect*. 2006;53(3):166–74.
 31. Swamydas M, Lionakis MS. Isolation, purification and labeling of mouse bone marrow neutrophils for functional studies and adoptive transfer experiments. *J Visualized Experiments: JoVE*. 2013;77:e50586.
 32. Tchalla EYI, Bhalla M, Wohlfert EA, Bou Ghanem EN. Neutrophils are required during immunization with the pneumococcal conjugate vaccine for protective antibody responses and host defense against infection. *J Infect Dis*. 2020.
 33. Bhalla M, Simmons SR, Abamonte A, Herring SE, Roggensack SE, Bou Ghanem EN. Extracellular adenosine signaling reverses the age-driven decline in the ability of neutrophils to kill *Streptococcus pneumoniae*. *Aging Cell*. 2020;19(10):e13218.
 34. Zhou Y, Tong L, Chu X, Deng F, Tang J, Tang Y, et al. The Adenosine A1 receptor antagonist DPCPX inhibits Tumor Progression via the ERK/JNK pathway in renal cell carcinoma. *Cell Physiol Biochem*. 2017;43(2):733–42.
 35. Zhang X, Xia J, Qian D, Wang Y, Lin Y, Huang X, et al. An adenosine A1 agonist 2-chloro-N6 cyclopentyladenosine inhibits the angiotensin II-induced cardiomyocyte hypertrophy through the calcineurin pathway. *Cardiology*. 2014;129(3):153–62.
 36. Yao L, McFarland K, Fan P, Jiang Z, Ueda T, Diamond I. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. *Proc Natl Acad Sci U S A*. 2006;103(20):7877–82.
 37. Phillis JW. The selective adenosine A2 receptor agonist, CGS 21680, is a potent depressant of cerebral cortical neuronal activity. *Brain Res*. 1990;509(2):328–30.
 38. Herbold W, Maus R, Hahn I, Ding N, Srivastava M, Christman JW, et al. Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. *Infect Immun*. 2010;78(6):2620–30.
 39. Herring SE, Mao S, Bhalla M, Tchalla EYI, Kramer JM, Bou Ghanem EN. Mitochondrial ROS production by neutrophils is required for host antimicrobial function against *Streptococcus pneumoniae* and is controlled by A2B adenosine receptor signaling. *PLoS Pathog*. 2022;18(11):e1010700.
 40. Reutershan J, Morris MA, Burcin TL, Smith DF, Chang D, Saprito MS, et al. Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung. *J Clin Invest*. 2006;116(3):695–702.
 41. Williams MR, Azcutia V, Newton G, Alcaide P, Luscinskas FW. Emerging mechanisms of neutrophil recruitment across endothelium. *Trends Immunol*. 2011;32(10):461–9.
 42. Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. *Nat Rev Microbiol*. 2003;1(1):17–24.
 43. Pirofski LA, Casadevall A. The damage-response framework of microbial pathogenesis and infectious diseases. *Adv Exp Med Biol*. 2008;635:135–46.
 44. Pirofski LA, Casadevall A. Pathogenesis of COVID-19 from the perspective of the damage-response Framework. *mBio*. 2020;11(4).
 45. Burgoyne RA, Fisher AJ, Borthwick LA. The role of epithelial damage in the Pulmonary Immune Response. *Cells*. 2021;10(10).
 46. Bhalla M, Hui Yeoh J, Lamneck C, Herring SE, Tchalla EYI, Heinzinger LR, et al. A1 adenosine receptor signaling reduces *Streptococcus pneumoniae* adherence to pulmonary epithelial cells by targeting expression of platelet-activating factor receptor. *Cell Microbiol*. 2020;22(2):e13141.
 47. Simmons SR, Bhalla M, Herring SE, Tchalla EYI, Bou Ghanem EN. Older but not Wiser: the age-driven changes in neutrophil responses during pulmonary infections. *Infect Immun*. 2021;89(4).
 48. Garvy BA, Harmsen AG. The importance of neutrophils in resistance to pneumococcal pneumonia in adult and neonatal mice. *Inflammation*. 1996;20(5):499–512.
 49. Hahn I, Klaus A, Janze AK, Steinwede K, Ding N, Bohling J, et al. Cathepsin G and neutrophil elastase play critical and nonredundant roles in lung-protective immunity against *Streptococcus pneumoniae* in mice. *Infect Immun*. 2011;79(12):4893–901.
 50. Kulkarni U, Zemans RL, Smith CA, Wood SC, Deng JC, Goldstein DR. Excessive neutrophil levels in the lung underlie the age-associated increase in influenza mortality. *Mucosal Immunol*. 2019;12(2):545–54.
 51. Toapanta FR, Ross TM. Impaired immune responses in the lungs of aged mice following influenza infection. *Respir Res*. 2009;10:112.
 52. Craig A, Mai J, Cai S, Jeyaseelan S. Neutrophil recruitment to the lungs during bacterial pneumonia. *Infect Immun*. 2009;77(2):568–75.
 53. Bou Ghanem EN, Lee JN, Joma BH, Meydani SN, Leong JM, Panda A. The alpha-tocopherol form of vitamin E boosts elastase activity of human PMNs and their ability to kill *Streptococcus pneumoniae*. *Front Cell Infect Microbiol*. 2017;7:161.
 54. Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, et al. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. *Blood*. 2014;123(2):239–48.
 55. Sapey E, Patel JM, Greenwood HL, Walton GM, Hazeldine J, Sadhra C, et al. Pulmonary infections in the Elderly lead to impaired neutrophil targeting, which is improved by Simvastatin. *Am J Respir Crit Care Med*. 2017;196(10):1325–36.
 56. Nomellini V, Brubaker AL, Mahbub S, Palmer JL, Gomez CR, Kovacs EJ. Dysregulation of neutrophil CXCR2 and pulmonary endothelial icam-1 promotes age-related pulmonary inflammation. *Aging Dis*. 2012;3(3):234–47.
 57. Ren Z, Gay R, Thomas A, Pae M, Wu D, Logsdon L, et al. Effect of age on susceptibility to *Salmonella Typhimurium* infection in C57BL/6 mice. *J Med Microbiol*. 2009;58(Pt 12):1559–67.
 58. Van Avondt K, Strecker J-K, Tulotta C, Minnerup J, Schulz C, Soehnlein O. Neutrophils in aging and aging-related pathologies. *Immunol Rev*. 2023;314(1):357–75.
 59. Shi L, Wu Z, Miao J, Du S, Ai S, Xu E, et al. Adenosine interaction with adenosine receptor A2a promotes gastric cancer metastasis by enhancing PI3K-AKT-mTOR signaling. *Mol Biol Cell*. 2019;30(19):2527–34.
 60. Cronstein BN, Levin RI, Phillips M, Hirschhorn R, Abramson SB, Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. *J Immunol*. 1992;148(7):2201–6.
 61. Felsch A, Stocker K, Borchard U. Phorbol ester-stimulated adherence of neutrophils to endothelial cells is reduced by adenosine A2 receptor agonists. *J Immunol*. 1995;155(1):333–8.
 62. Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. *J Clin Invest*. 2005;115(1):35–43.
 63. Fernandez LG, Sharma AK, LaPar DJ, Kron IL, Laubach VE. Adenosine A1 receptor activation attenuates lung ischemia-reperfusion injury. *J Thorac Cardiovasc Surg*. 2013;145(6):1654–9.
 64. Ngamsri KC, Wagner R, Vollmer I, Stark S, Reutershan J. Adenosine receptor A1 regulates polymorphonuclear cell trafficking and microvascular permeability in lipopolysaccharide-induced lung injury. *J Immunol*. 2010;185(7):4374–84.
 65. Gazoni LM, Walters DM, Unger EB, Linden J, Kron IL, Laubach VE. Activation of A1, A2a, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury. *J Thorac Cardiovasc Surg*. 2010;140(2):440–6.
 66. Aeffner F, Woods PS, Davis IC. Activation of A1-adenosine receptors promotes leukocyte recruitment to the lung and attenuates acute lung injury in mice infected with influenza A/WSN/33 (H1N1) virus. *J Virol*. 2014;88(17):10214–27.

67. Lee JS, Yilmaz O. Unfolding role of a Danger Molecule Adenosine Signaling in Modulation of Microbial infection and host cell response. *Int J Mol Sci.* 2018;19(1).
68. Rolband GC, Furth ED, Staddon JM, Rogus EM, Goldberg AP. Effects of age and adenosine in the modulation of insulin action on rat adipocyte metabolism. *J Gerontol.* 1990;45(5):B174–8.
69. Waldo GL, Northup JK, Perkins JP, Harden TK. Characterization of an altered membrane form of the beta-adrenergic receptor produced during agonist-induced desensitization. *J Biol Chem.* 1983;258(22):13900–8.
70. Yuan L, Barbash S, Kongsamut S, Eishingdrelo A, Sakmar TP, Eishingdrelo H. 14-3-3 signal adaptor and scaffold proteins mediate GPCR trafficking. *Sci Rep.* 2019;9(1):11156.
71. Shenoy SK, Lefkowitz RJ. β -Arrestin-mediated receptor trafficking and signal transduction. *Trends Pharmacol Sci.* 2011;32(9):521–33.
72. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. *Blood.* 2004;104(13):3986–92.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.